Wei He1, Peter Zhou2, Zhigang Chang3, Baoling Liu4, Xuefeng Liu5, Yanming Wang6, Yongqing Li4, Hasan B Alam7. 1. Department of Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China; Department of Surgery, University of Michigan, Ann Arbor, Michigan. 2. Department of Surgery, University of Michigan, Ann Arbor, Michigan; Harvard University, Cambridge, Massachusetts. 3. Department of Surgery, University of Michigan, Ann Arbor, Michigan; Department of Surgical ICU, Beijing Hospital Ministry of Health, Beijing, China. 4. Department of Surgery, University of Michigan, Ann Arbor, Michigan. 5. Department of Systems Leadership and Effectiveness Science, University of Michigan School of Nursing, Ann Arbor, Michigan. 6. Department of Biochemistry and Molecular Biology, Pennsylvania State University, Pennsylvania. 7. Department of Surgery, University of Michigan, Ann Arbor, Michigan. Electronic address: alamh@med.umich.edu.
Abstract
BACKGROUND: We have recently shown that inhibition of peptidylarginine deiminase (PAD) improves survival in a rodent model of lethal cecal ligation and puncture. The roles of PAD inhibitors in hemorrhagic shock (HS), however, are largely unknown. The goal of this study was to investigate the effects of YW3-56, a novel PAD inhibitor, on survival after severe HS. METHODS: Mouse macrophages were exposed to hypoxic conditions followed by reoxygenation in the presence or absence of YW3-56. Enzyme-linked immunosorbent assay (ELISA) was performed to measure levels of secreted tumor necrosis factor α and interleukin-6 in the culture medium. Cell viability was determined by methyl thiazolyl tetrazolium assay. In the survival experiment, anesthetized male Wistar-Kyoto rats (n = 10/group) were subjected to 55% blood loss, and treated with or without YW3-56 (10 mg/kg, intraperitoneally). Survival was monitored for 12 h. In the nonsurvival experiment, morphologic changes of the lungs were examined. Levels of circulating cytokine-induced neutrophil chemoattractant 1 (CINC-1) and myeloperoxidase (MPO) in the lungs were measured by ELISA. Expression of lung intercellular adhesion molecules-1 (ICAM-1) was also determined by Western blotting. RESULTS: Hypoxia/reoxygenation (H/R) insult induced tumor necrosis factor α and interleukin-6 secretion from macrophages, which was significantly attenuated by YW3-56 treatment. YW3-56 treatment also increased cell viability when macrophages were exposed to H/R up to 6/15 h and improved survival rate from 20% to 60% in lethal HS rat model. Compared to the sham groups, pulmonary MPO activity and ICAM-1 expression in the HS group were significantly increased, and acute lung injury was associated with a higher degree of CINC-1 levels in serum. Intraperitoneal delivery of YW3-56 significantly reduced pulmonary MPO and ICAM-1 expression and attenuated acute lung injury. CONCLUSIONS: Our results demonstrate for the first time that administration of YW3-56, a novel PAD inhibitor, can improve survival in a rat model of HS and in a cell culture model of H/R. The survival advantage is associated with an attenuation of local and systemic pro-inflammatory cytokines and the protection against acute lung injury after hemorrhage. Thus, PAD inhibition may represent a novel and promising therapeutic strategy for severe HS.
BACKGROUND: We have recently shown that inhibition of peptidylarginine deiminase (PAD) improves survival in a rodent model of lethal cecal ligation and puncture. The roles of PAD inhibitors in hemorrhagic shock (HS), however, are largely unknown. The goal of this study was to investigate the effects of YW3-56, a novel PAD inhibitor, on survival after severe HS. METHODS:Mouse macrophages were exposed to hypoxic conditions followed by reoxygenation in the presence or absence of YW3-56. Enzyme-linked immunosorbent assay (ELISA) was performed to measure levels of secreted tumor necrosis factor α and interleukin-6 in the culture medium. Cell viability was determined by methyl thiazolyl tetrazolium assay. In the survival experiment, anesthetized male Wistar-Kyoto rats (n = 10/group) were subjected to 55% blood loss, and treated with or without YW3-56 (10 mg/kg, intraperitoneally). Survival was monitored for 12 h. In the nonsurvival experiment, morphologic changes of the lungs were examined. Levels of circulating cytokine-induced neutrophil chemoattractant 1 (CINC-1) and myeloperoxidase (MPO) in the lungs were measured by ELISA. Expression of lung intercellular adhesion molecules-1 (ICAM-1) was also determined by Western blotting. RESULTS:Hypoxia/reoxygenation (H/R) insult induced tumor necrosis factor α and interleukin-6 secretion from macrophages, which was significantly attenuated by YW3-56 treatment. YW3-56 treatment also increased cell viability when macrophages were exposed to H/R up to 6/15 h and improved survival rate from 20% to 60% in lethal HS rat model. Compared to the sham groups, pulmonary MPO activity and ICAM-1 expression in the HS group were significantly increased, and acute lung injury was associated with a higher degree of CINC-1 levels in serum. Intraperitoneal delivery of YW3-56 significantly reduced pulmonary MPO and ICAM-1 expression and attenuated acute lung injury. CONCLUSIONS: Our results demonstrate for the first time that administration of YW3-56, a novel PAD inhibitor, can improve survival in a rat model of HS and in a cell culture model of H/R. The survival advantage is associated with an attenuation of local and systemic pro-inflammatory cytokines and the protection against acute lung injury after hemorrhage. Thus, PAD inhibition may represent a novel and promising therapeutic strategy for severe HS.
Authors: Alexander S Savchenko; Julian I Borissoff; Kimberly Martinod; Simon F De Meyer; Maureen Gallant; Luise Erpenbeck; Alexander Brill; Yanming Wang; Denisa D Wagner Journal: Blood Date: 2013-11-07 Impact factor: 22.113
Authors: Yongqing Li; Baoling Liu; Eugene Y Fukudome; Jenifer Lu; Wei Chong; Guang Jin; Zhengcai Liu; George C Velmahos; Marc Demoya; David R King; Hasan B Alam Journal: Surgery Date: 2011-09 Impact factor: 3.982
Authors: Eugene Y Fukudome; Yongqing Li; Ashley R Kochanek; Jennifer Lu; Eleanor J Smith; Baoling Liu; Kyuseok Kim; George C Velmahos; Marc A deMoya; Hasan B Alam Journal: Surgery Date: 2012-05-30 Impact factor: 3.982
Authors: Stefania D'Alessio; Hang Cheng; Liam Eaton; Igor Kraev; Matthew E Pamenter; Sigrun Lange Journal: Int J Mol Sci Date: 2022-04-23 Impact factor: 6.208
Authors: Umar F Bhatti; Aaron M Williams; Ranganath G Kathawate; Panpan Chang; Jing Zhou; Ben E Biesterveld; Zhenyu Wu; Julia Dahl; Baoling Liu; Yongqing Li; Hasan B Alam Journal: Trauma Surg Acute Care Open Date: 2019-09-17